Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617 · AFFIRM Phase 3Recruiting
- Lead sponsor
- Gilead Sciences (Industry)
- Enrollment
- 402 (estimated)
- Start date
- 7 Sep 2023
- Primary completion
- Aug 2030 (estimated)
- Study completion
- 1 Aug 2030
- Last update posted
- 6 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 3
Interventions
- Seladelpar Drug
- Placebo Drug
Conditions and primary outcome
- Primary Biliary Cholangitis
Primary outcome
Event Free Survival (EFS) (36 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06051617.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06051617 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.